You've lost the weight on a weekly injection. Now the injections are the part you'd like to be done with, whether that's the needle, the refrigeration, the travel hassle, or the cost. Until recently the realistic choices were to stay on the shot, step down to a lower dose, or stop. Now there are two pill routes. If you're on Wegovy 2.4 mg, the Wegovy label itself allows a switch to Wegovy 25 mg tablets. And a randomized trial published in 2026 tested switching from injectable tirzepatide or semaglutide to a different daily pill, orforglipron.
This guide is mainly about that trial: what it found, how it compares with your other options, and what it left unanswered.
The short version
In the one trial so far, people who switched from injectable tirzepatide or semaglutide to the daily pill orforglipron kept most of their weight loss over the following year. People switched to a placebo pill kept far less, and most of them needed to be put back on active medication.
The catch is that the trial compared the pill against stopping. It did not compare the pill against staying on the injection. So it shows that switching beats quitting. It can't tell you how switching compares with carrying on as you are.
If you're on Wegovy: the on-label switch
As of September 2026, the Wegovy prescribing information lets adults taking Wegovy 2.4 mg injection switch to Wegovy 25 mg tablets, starting the tablets one week after the last injection. It also covers switching back: start the 2.4 mg injection the day after stopping the tablets, or consider 1.7 mg injection if the 25 mg tablets aren't tolerated. That route stays with the same drug, semaglutide, and it's on the label. It is not what the trial below tested, so the trial's numbers don't tell you how well it holds weight. Our guide comparing the GLP-1 pills covers how the Wegovy pill is taken.
What the pill in the trial is
Orforglipron is a once-daily GLP-1 pill made by Eli Lilly and sold in the US as Foundayo. The FDA approved it for weight management on April 1, 2026. Unlike oral semaglutide, it can be taken at any time of day without food or water restrictions.
It is a less powerful weight-loss drug than the injections. In its main trial the highest dose produced an average 11.2% weight loss over 72 weeks (Wharton et al., The New England Journal of Medicine, 2025, DOI (external link)). In a head-to-head trial, injectable tirzepatide produced 20.2% and injectable semaglutide 13.7% over the same period (Aronne et al., The New England Journal of Medicine, 2025, DOI (external link)).
That gap matters for what follows. A drug doesn't need to be strong enough to produce a 20% loss in order to help you keep most of one. That is the idea the maintenance trial set out to test.
What the trial did
ATTAIN-MAINTAIN enrolled 376 adults at 29 US sites (Aronne et al., Nature Medicine, 2026, DOI (external link)). All of them had just finished 72 weeks on the highest dose they could tolerate of either injectable tirzepatide or injectable semaglutide in an earlier trial. None had type 2 diabetes.
They were then randomly assigned to a daily orforglipron pill or an identical placebo pill for 52 weeks. Neither they nor their doctors knew which they were taking. Everyone received healthy-lifestyle counseling throughout.
From week 24 onward, anyone who had regained half or more of their lost weight was given real orforglipron as a rescue. That was the ethical choice, and it also shapes how the results should be read (more on that below).
What it found
If you were coming off tirzepatide (205 people):
- People on the pill kept about 75% of their weight loss. People on placebo kept about 49%.
- About 44% of the pill group held on to at least four-fifths of their loss, against about 16% on placebo.
- In practical terms, the pill group had lost 21.5% of their starting weight on the injection and finished the year 16.8% below it. That's an average regain of about 5 kg (11 lb).
If you were coming off semaglutide (171 people):
- People on the pill kept about 79% of their weight loss. People on placebo kept about 38%.
- About 55% of the pill group held on to at least four-fifths of their loss, against about 7% on placebo.
- The pill group had lost 16.5% on the injection and finished the year 15.1% below their starting weight. That's an average regain of about 1 kg (2 lb).
Blood sugar, blood pressure, waist size, and cholesterol improvements were largely preserved in both pill groups.
Why the tirzepatide group regained more
The trial authors expected this. Tirzepatide acts on two hormone pathways (GIP and GLP-1), and orforglipron acts on one. Moving from a stronger two-pathway drug to a single-pathway pill is a bigger step down than moving between two GLP-1 drugs. The authors say this explanation still needs further study.
If you're on Zepbound or Mounjaro, the realistic expectation from this trial is that you'd keep most of your loss but give some back. If you're on Wegovy or Ozempic, the trial suggests you might give back very little.
What the switch felt like
One worry about switching is whether you'd have to start the pill at the bottom and climb the dose ladder again, with a fresh round of nausea. The trial tested a shortcut: people went straight from their injection to a mid-range dose of orforglipron, skipping the lowest starting doses.
It went reasonably well. In the first four weeks, about 1 in 10 people reported nausea, vomiting, or diarrhea, most of it mild to moderate. Nobody needed their dose reduced during that period. Over the full year, between 4.8% and 7.3% of people on the pill stopped it because of side effects.
There was one confirmed case of mild pancreatitis in the pill group, and a small number of people in both the pill and placebo groups had raised liver enzymes. The authors reported no liver safety signal overall.
What the trial can't tell you
These limits come from the paper itself, and they're significant.
- There was no "stay on the injection" group. This is the biggest one. The trial shows that switching to the pill beats switching to nothing. It doesn't show how switching compares with simply continuing your current injection, which in other trials has held or even extended weight loss.
- It ran for one year. Nobody knows yet whether the pill holds weight in year two or three.
- Rescue treatment blurs the placebo comparison. Because people on placebo who regained heavily were moved onto real medication, the placebo group's final numbers look better than true stopping would. By the end, only about 31% of the placebo group coming off tirzepatide, and 18% coming off semaglutide, had made it through without active medication.
- The population was narrow. All US sites, predominantly white, no type 2 diabetes.
- The manufacturer ran it. Eli Lilly funded the trial, and 8 of the 14 authors are Lilly employees. That's normal for a trial of this kind, and the design was randomized and double-blind, but it's worth knowing when the company also sells the pill.
- It's one trial. The authors call it the first of its kind. Nothing has replicated it yet.
How this fits with your other options
If you've reached a weight you're happy with, you now have more paths than "stay or stop." Here is how the evidence for each compares.
| Option | What the evidence shows |
|---|---|
| Stay on your current injection | Strongest evidence for keeping, and sometimes extending, your results. |
| Step down to a lower injection dose | One randomized trial. People who dropped to tirzepatide 5 mg kept most of their loss, but about 1 in 4 regained half or more. See tapering vs. staying on a maintenance dose. |
| Switch to a daily pill (orforglipron) | One randomized trial, covered here. Most of the loss kept, more so coming off semaglutide than tirzepatide. Not compared against staying on the injection. |
| Switch Wegovy 2.4 mg injection to Wegovy 25 mg tablets | Allowed by the Wegovy label. Not tested in the trial covered here. |
| Space injections further apart | No randomized trial yet. See stretching your dose past 7 days. |
| Stop | Regain is the expected result. See stopping a GLP-1. |
Nobody has tested these options against each other. Choosing between a lower injection dose and a pill currently comes down to your preferences, your side effects, and what you can afford and access, more than to any head-to-head data.
Questions worth raising with your prescriber
- Given which injection I'm on, how much regain should I realistically expect if I switch?
- What would we treat as the signal to switch back? A specific number of pounds, or a percentage of what I lost?
- Would I start the pill at a mid-range dose, as in the trial, or at the bottom?
- What will the pill cost me compared with my injection, on my plan? Our guide to manufacturer savings cards covers the current Foundayo program.
- Is a lower dose of my current injection a better fit for me than switching drugs?
The bottom line
If the injection is working and you can keep getting it, there's no evidence that switching improves anything. If you're going to come off the injection anyway, this trial suggests that moving to a pill is a much better plan than stopping outright.
Study findings above are attributed to their authors and were located via PubMed. This guide is general education and peer information, not medical advice. Decisions about switching or changing your medication belong with the prescriber who knows your history.